Abstract
Benign prostatic hyperplasia (BPH) and prostate cancer are common diseases of the prostate gland. BPH is commonly treated by pharmaceutical products, which commonly improve symptoms but are often off-set by adverse events including erectile dysfunction, which affect quality of life. Similarly, a variety of treatment options exist for the treatment of prostate cancer. The applicability of these prostate cancer treatments is reliant on stage of disease. Whilst effectiveness of prostate cancer treatments may vary, common adverse effects include erectile dysfunction, incontinence and lower quality of life. Early evidence from systematic reviews has suggested that diet and lifestyle factors may be beneficial in reducing the risk of cancer. Lycopene, a member of the carotenoid family, found commonly in red pigmented fruit and vegetables has been established as having strong antioxidant and pro-oxidant properties. This chapter examines the current evidence on the use of lycopene as a preventive agent for prostate disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ansari M, Gupta N (2003) A comparison of lycopene and orchidectomy vs orchidectomy alone in the management of advanced prostate cancer. BJU Int 92:375–378
Bailey R, Gahche J, Lenito C et al (2011) Dietary supplement use in the United States, 2003–2006. J Nutr 141:261–266
Berry S, Coffey D, Walsh P, Ewing L (1984) The development of human benign prostatic hyperplasia with age. J Urol 132:474–479
Chan J, Gann P, Giovannucci E (2005) Role of diet in prostate cancer development and progression. J Clin Oncol 23:8152–8160
Coyne K, Sexton C, Thompson C et al (2009) The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 104:352–360
Dennert G, Zwahlen M, Brinkman M, Vinceti M, Zeegers M, Horneber M (2011) Selenium for preventing cancer. Cochrane Database Syst Rev. Issue 5. Art. no.: CD005195. doi: 005110.001002/14651858.CD14005195.pub14651852
Etminan M, Takkouche B, Caamano-Isorna F (2004) The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomark Prev 13:340–345
Haseen F, Cantwell M, O’Sullivan J, Murray L (2009) Is there a benefit from lycopene supplementation in men with prostate cancer? A systematic review. Prostate Cancer Prostatic Dis 12:325–332
Heidenreich A, Bellmunt J, Bolla M et al (2011) EAU Guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59:61–71
Hoffman R, MacDonald R, Wilt T. Laser prostatectomy for benign prostatic obstruction. Cochrane Database Syst Rev. Issue 1. Art. no.: CD001987. doi: 10.1002/14651858.CD001987.pub2
Ilic D, Misso M (2012) Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review. Maturitas 72:269–276
Ilic D, Forbes K, Hassad C (2011) Lycopene for the prevention of prostate cancer. Cochrane Database Syst Rev. Issue 11. Art. no.: CD008007. doi: 10.1002/14651858.CD008007.pub2)
Ilic D, Neuberger M, Djulbegovic M, Dahm P (2013) Screening for prostate cancer. Cochrane Database Syst Rev. Issue 1. Art. no.: CD004720. doi: 004710.001002/14651858.CD14004720.pub14651853
Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90
Karas M, Amir H, Fishman D et al (2000) Lycopene interferes with cell cycle progression and insulin-like growth factor I signaling in mammary cancer cells. Nutr Cancer 26:101–111
Matsushima N, Shidoji Y, Nishiwaki S, Yamada T, Moriwaki H, Muto Y (1995) Suppression by carotenoids of microcystin-induced morphological changes in mouse hepatocytes. Lipids 30:1029–1034
McVary K, Roehrborn C, Avins A et al (2011) Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 185:1793–1803
Porrini M, Riso P (2005) What are typical lycopene intakes? J Nutr 135:2042S–2045S
Schwarz S, Obermuller-Jevic U, Hellmis E, Koch W, Jacobi G, Biesalski H (2008) Lycopene inhibits disease progression in patients with benign prostate hyperplasia. J Nutr 138:49–53
Stratton J, Godwin M (2011) The effect of supplemental vitamins and minerals on the development of prostate cancer: a systematic review and meta-analysis. Fam Pract 28:243–252
Tacklind J, Fink H, MacDonald R, Rutks I, Wilt T (2010) Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev. Issue 10. Art. no.: CD006015. doi: 10.1002/14651858.CD006015.pub3
Wang X (2012) Lycopene metabolism and its biological significance. Am J Clin Nutr 96:1214S–1222S
Wertz K, Siler U, Goralczyk R (2004) Lycopene: modes of action to promote prostate health. Arch Biochem Biophys 430:127–134
Wilt T, Ishani A (1998) Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev. Issue 1. Art. no.: CD001044. doi: 10.1002/14651858.CD001044
Wilt T, MacDonald R, Hagerty K, Schellhammer P, Kramer B (2008) 5-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database of Systematic Reviews. ;Issue 2. Art. no.: CD007091. DOI: 10.1002/14651858.CD007091
World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity and the prevention of cancer: A global perspective. AICR, Washington DC
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ilic, D. (2014). Lycopene for the Prevention and Treatment of Prostate Disease. In: Cuzick, J., Thorat, M. (eds) Prostate Cancer Prevention. Recent Results in Cancer Research, vol 202. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-45195-9_13
Download citation
DOI: https://doi.org/10.1007/978-3-642-45195-9_13
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-45194-2
Online ISBN: 978-3-642-45195-9
eBook Packages: MedicineMedicine (R0)